Comparative safety of anti-epileptic drugs among infants and children exposed in utero or during breastfeeding: Protocol for a systematic review and network meta-analysis

Systematic Reviews

Volumn 3, Issue 1, 2015, Pages

  Tricco, Andrea C ^a   Cogo, Elise ^a   Angeliki, Veroniki A ^a   Soobiah, Charlene ^a,b   Hutton, Brian ^c   Hemmelgarn, Brenda R ^d   Moher, David ^c   Finkelstein, Yaron ^e,f   Straus, Sharon E ^a,f  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

Anti epileptic drug; Breastfeeding; Comparative safety; Congenital malformation; Epilepsy; Fetus; Infant; Network meta analysis; Pregnancy; Systematic review

Indexed keywords

ANTICONVULSIVE AGENT;

ARTICLE; BREAST FEEDING; CANADA; COGNITIVE DEFECT; COGNITIVE DEVELOPMENT; CONGENITAL MALFORMATION; DRUG SAFETY; EPILEPSY; FETUS WASTAGE; GROWTH RETARDATION; HUMAN; INFANT MORTALITY; INFANTILE SPASM; META ANALYSIS; METHODOLOGY; PREGNANT WOMAN; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCIENTIFIC LITERATURE; SMALL FOR DATE INFANT; SPONTANEOUS ABORTION; SYSTEMATIC REVIEW; CHEMICALLY INDUCED DISORDER; CHILD; FEMALE; INFANT; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL EXPOSURE; PRESCHOOL CHILD; REVIEW;

ANTICONVULSANTS; BREAST FEEDING; CHILD; CHILD, PRESCHOOL; EPILEPSY; FEMALE; HUMANS; INFANT; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS;

EID: 84907267808     PISSN: None     EISSN: 20464053     Source Type: Journal    
DOI: 10.1186/2046-4053-3-68     Document Type: Article

References (62)

1. Hauser WA, Hesdorffer D. Epilepsy, Frequency, Causes and Consequences 1990, New York: Demos Publications.
2. Wiebe S, Bellhouse DR, Fallahay C, Eliasziw M. Burden of epilepsy: the Ontario Health Survey. Can J Neurol Sci 1999, 26(4):263-270.
3. Sperling MR. The consequences of uncontrolled epilepsy. CNS Spectr 2004, 9(2):98-101. 106-109.
4. Jones MW. Consequences of epilepsy: why do we treat seizures?. Can J Neurol Sci 1998, 25(4):S24-S26.
5. Dickenson AH, Ghandehari J. Anti-convulsants and anti-depressants. Handb Exp Pharmacol 2007, 177:145-177.
6. Stefani A, Spadoni F, Bernardi G. Voltage-activated calcium channels: targets of antiepileptic drug therapy?. Epilepsia 1997, 38(9):959-965.
7. Snutch TP, Reiner PB. Ca2+ channels: diversity of form and function. Curr Opin Neurobiol 1992, 2(3):247-253.
8. Spina E, Perugi G. Antiepileptic drugs: indications other than epilepsy. Epileptic Disord 2004, 6(2):57-75.
9. Harden CL, Pennell PB, Koppel BS, Hovinga CA, Gidal B, Meador KJ, Hopp J, Ting TY, Hauser WA, Thurman D, Kaplan PW, Robinson JN, French JA, Wiebe S, Wilner AN, Vazquez B, Holmes L, Krumholz A, Finnell R, Shafer PO, Le Guen CL., American Academy of Neurology; American Epilepsy Society Management issues for women with epilepsy-focus on pregnancy (an evidence-based review): III. Vitamin K, folic acid, blood levels, and breast-feeding: report of the quality standards subcommittee and therapeutics and technology assessment subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009, 50(5):1247-1255. American Academy of Neurology; American Epilepsy Society.
10. Harden CL, Meador KJ, Pennell PB, Hauser WA, Gronseth GS, French JA, Wiebe S, Thurman D, Koppel BS, Kaplan PW, Robinson JN, Hopp J, Ting TY, Gidal B, Hovinga CA, Wilner AN, Vazquez B, Holmes L, Krumholz A, Finnell R, Hirtz D, Le Guen C., American Academy of Neurology; American Epilepsy Society Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009, 50(5):1237-1246. American Academy of Neurology; American Epilepsy Society.
11. Samren EB, van Duijn CM, Koch S, Hiilesmaa VK, Klepel H, Bardy AH, Mannagetta GB, Deichl AW, Gaily E, Granstrom ML, Meinardi H, Grobbee DE, Hofman A, Janz D, Lindhout D. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997, 38(9):981-990.
12. Meador K, Reynolds MW, Crean S, Fahrbach K, Probst C. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res 2008, 81(1):1-13.
13. Adab N, Jacoby A, Smith D, Chadwick D. Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2001, 70(1):15-21.
14. Adab N, Kini U, Vinten J, Ayres J, Baker G, Clayton-Smith J, Coyle H, Fryer A, Gorry J, Gregg J, Mawer G, Nicolaides P, Pickering L, Tunnicliffe L, Chadwick DW. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2004, 75(11):1575-1583.
15. Gaily E, Kantola-Sorsa E, Hiilesmaa V, Isoaho M, Matila R, Kotila M, Nylund T, Bardy A, Kaaja E, Granstrom ML. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 2004, 62(1):28-32.
16. Meador KJ, Baker GA, Browning N, Clayton-Smith J, Combs-Cantrell DT, Cohen M, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW., for the NEAD Study Group Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 2009, 360(16):1597-1605. for the NEAD Study Group.
17. Holmes LB, Wyszynski DF, Lieberman E. The AED (antiepileptic drug) pregnancy registry: a 6-year experience. Arch Neurol 2004, 61(5):673-678.
18. Reinisch JM, Sanders SA, Mortensen EL, Rubin DB. In utero exposure to phenobarbital and intelligence deficits in adult men. JAMA 1995, 274(19):1518-1525.
19. Morrow J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell R, Irwin B, McGivern RC, Morrison PJ, Craig J. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006, 77(2):193-198.
20. Meador KJ, Baker GA, Finnell RH, Kalayjian LA, Liporace JD, Loring DW, Mawer G, Pennell PB, Smith JC, Wolff MC., NEAD Study Group In utero antiepileptic drug exposure: fetal death and malformations. Neurology 2006, 67(3):407-412. NEAD Study Group.
21. Vajda FJ, Hitchcock A, Graham J, Solinas C, O'Brien TJ, Lander CM, Eadie MJ. Foetal malformations and seizure control: 52 months data of the Australian Pregnancy Registry. Eur J Neurol 2006, 13(6):645-654.
22. Holmes LB, Baldwin EJ, Smith CR, Habecker E, Glassman L, Wong SL, Wyszynski DF. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 2008, 70(22 Pt 2):2152-2158.
23. Meador KJ, Penovich P, Baker GA, Pennell PB, Bromfield E, Pack A, Liporace JD, Sam M, Kalayjian LA, Thurman DJ, Moore E, Loring DW., NEAD Study Group Antiepileptic drug use in women of childbearing age. Epilepsy Behav 2009, 15(3):339-343. NEAD Study Group.
24. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L. Reporting Guidelines for Systematic Review Protocols. 19th Cochrane Colloquium: 19-22 October 2011; Madrid, Spain
25. Ross CJ, Visscher H, Sistonen J, Brunham LR, Pussegoda K, Loo TT, Rieder MJ, Koren G, Carleton BC, Hayden MR., CPNDS Consortium The Canadian Pharmacogenomics Network for Drug Safety: a model for safety pharmacology. Thyroid 2010, 20(7):681-687. CPNDS Consortium.
26. Eypasch E, Lefering R, Kum CK, Troidl H. Probability of adverse events that have not yet occurred: a statistical reminder. BMJ 1995, 311(7005):619-620.
27. Atkins D. Creating and synthesizing evidence with decision makers in mind: integrating evidence from clinical trials and other study designs. Med Care 2007, 45(10 Supl 2):S16-S22.
28. Health Canada: Drug Product Database http://www.hc-sc.gc.ca/dhp-mps/prodpharma/databasdon/index-eng.php.
29. United States National Library of Medicine's ChemIDPlus Lite Database http://chem.sis.nlm.nih.gov/chemidplus/chemidlite.jsp.
30. Canadian Pharmacists Association: E-CPS (Compendium of Pharmaceuticals and Specialties) http://www.e-therapeutics.ca/home.whatsnew.action.
31. Epilepsy Canada: Anticonvulsant Medications http://www.epilepsy.ca/en-CA/Diagnosis-and-Treatment/Anticonvulsant-Medications.html.
32. Epilepsy Ontario: Anticonvulsant/Anti-Seizure Medication from A to Z http://epilepsyontario.org/anticonvulsantanti-seizure-medication-from-a-to-z/.
33. Sampson M, McGowan J, Cogo E, Grimshaw J, Moher D, Lefebvre C. An evidence-based practice guideline for the peer review of electronic search strategies. J Clin Epidemiol 2009, 62(9):944-952.
34. Canadian Agency for Drugs and Technologies in Health: Grey Matters: A Practical Search Tool for Evidence-Based Medicine http://www.cadth.ca/resources/grey-matters.
35. Adab N, Tudur SC, Vinten J, Williamson P, Winterbottom J. Common antiepileptic drugs in pregnancy in women with epilepsy. Cochrane Database Syst Rev 2004, 3:CD004848.
36. Banach R, Boskovic R, Einarson T, Koren G. Long-term developmental outcome of children of women with epilepsy, unexposed or exposed prenatally to antiepileptic drugs: a meta-analysis of cohort studies. Drug Saf 2010, 33(1):73-79.
37. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977, 33(1):159-174.
38. Synthesi.SR http://knowledgetranslation.ca/sysrev/login.php.
39. Stone PW. Popping the (PICO) question in research and evidence-based practice. Appl Nurs Res 2002, 15(3):197-198.
40. Cochrane Effective Practice and Organization of Care Group Draft Risk of Bias Tool http://epoc.cochrane.org/epoc-author-resources.
41. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
42. Santaguida PL, Raina P, Ismaila A. The Development of the McHarm Quality Assessment Scale for Adverse Events 2008, Hamilton, Ontario: McMaster University.
43. Raudenbush SW. Analyzing Effect Sizes: Random Effects Models. The Handbook of Research Synthesis and Meta-analysis 2009, 295-315. New York: Russell Sage Foundation, Cooper H, Hedges LV, Valentine JC, 2.
44. Viechtbauer W. Bias and efficiency of meta-analytic variance estimators in the random-effects model. J Educ Behav Stat 2005, 30(3):261-293.
45. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21(11):1539-1558.
46. Viechtbauer W. Confidence intervals for the amount of heterogeneity in meta-analysis. Stat Med 2007, 26(1):37-52.
47. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions 2009, The Cochrane Collaboration, http://www.cochrane.org/handbook.
48. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 2004, 23(9):1351-1375.
49. Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 2007, 26(1):53-77.
50. Littell JH, Corcoran J, Pillai V. Systematic Reviews and Meta-Analysis 2008, New York: Oxford University Press.
51. Carpenter J, Rucker G, Schwarzer G. Assessing the sensitivity of meta-analysis to selection bias: a multiple imputation approach. Biometrics 2011, 67(3):1066-1072.
52. Conducting Meta-Analyses in R with the metafor Package http://www.jstatsoft.org/v36/i03/.
53. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011, 64(2):163-171.
54. Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods 2012, 3(2):80-97.
55. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003, 326(7387):472.
56. Veroniki AA, Vasiliadis HS, Higgins JP, Salanti G. Evaluation of inconsistency in networks of interventions. Int J Epidemiol 2013, 42(1):332-345.
57. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med 2010, 29(7-8):932-944.
58. White IR, Barrett JK, Jackson D, Higgins JPT. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods 2012, 3(2):111-125.
59. Jackson D, Barrett JK, Stephen R, White IR, Higgins JPT. A design-by-treatment interaction model for network meta-analysis with random inconsistency effects. Stat Med 2014, In press.
60. White IR. Multivariate random-effects meta-regression: updates to mvmeta. Stata J 2011, 11(2):255-270.
61. Centers for Disease Control and Prevention Unintended Pregnancy Prevention http://www.cdc.gov/reproductivehealth/unintendedpregnancy/, Centers for Disease Control and Prevention.
62. Yerby MS. Pregnancy, teratogenesis, and epilepsy. Neurol Clin 1994, 12(4):749-771.